(MedPage Today) — The combination of investigational sintilimab with axitinib (Inlyta) showed promise in patients with fumarate hydratase (FH)-deficient renal cell carcinoma (RCC), according to a phase II nonrandomized trial in China.
Among 41…
Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/117022
Author :
Publish date : 2025-08-15 18:21:00
Copyright for syndicated content belongs to the linked Source.
